pyrazines has been researched along with Shock, Septic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hobeika, L; Self, SE; Velez, JC | 1 |
| Bose, P; Gandhi, D; Ghabach, B; Ozer, H; Thompson, C | 1 |
| Chen, SJ; Liao, MH; Wu, CC; Yen, MH | 1 |
3 other study(ies) available for pyrazines and Shock, Septic
| Article | Year |
|---|---|
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.
Topics: Adult; Boronic Acids; Bortezomib; Humans; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Male; Pyrazines; Remission Induction; Shock, Septic | 2009 |
Tetramethylpyradizine prevents inducible NO synthase expression and improves survival in rodent models of endotoxic shock.
Topics: Animals; Aorta; Blood Pressure; Disease Models, Animal; Heart Rate; In Vitro Techniques; Lipopolysaccharides; Lung; Male; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Norepinephrine; Pyrazines; Rats; Rats, Inbred WKY; Shock, Septic; Tumor Necrosis Factor-alpha; Vasodilator Agents | 1999 |